Search


FDA requires updated safety labelling for weight-loss medication

The US Food and Drug Administration now requires GLP-1 medication to include a non-arteritic anterior ischemic optic neuropathy warning

Healthcare professional in blue scrubs measuring a patient's waist circumference with a tape measure
Getty/FluxFactory

The US Food and Drug Administration (FDA) has updated safety labelling requirements for GLP-1 receptor agonist medications – requiring companies to make patients aware of an increased risk of a rare but sight-threatening eye condition.

The new requirement, which was published on the FDA website on 9 November, affects an increasingly popular class of medications that is used in the treatment of type 2 diabetes and obesity. GLP-1 medications include Ozempic, Wegovy and Mounjaro.

The FDA highlighted that it is informing patients and healthcare providers of “a potential increased risk” of non-arteritic anterior ischemic optic neuropathy (NAION) associated with the use of GLP-1 medications.

“The agency is requiring application holders for all GLP-1 RA medications to add information to the Warnings and Precautions section of labeling about the potential increased risk of NAION associated with use of these medications,” the FDA stated.

Detailing the symptoms of NAION, the FDA shared that the condition is associated with sudden, painless vision loss in one eye that patients may notice upon waking.

Patients may experience blurred or missing portions of vision, distortion of colours and reduced central sharpness.

“Patients should contact their health care professional right away if they have any of these symptoms,” the FDA highlighted.

The regulator noted that healthcare professionals should promptly refer patients to an ophthalmologist if NAION is suspected.

The updated safety labelling requirements follow an analysis of 126 randomised, controlled clinical trials across multiple GLP-1 medication types.

This found an occurrence of 6.4 NAION cases per 100,000 person-years (PY) in patients treated with GLP-1s, compared to 3.8 NAION cases per 100,000 PY in a comparator group not treated with GLP-1s.

Moorfields Eye Hospital has recently published a web page detailing the risks and benefits of GLP-1 medications.

Moorfields Eye Hospital consultant ophthalmic surgeon, Sharon Heng, emphasised the importance of viewing the eye health risks of GLP-1 medication in the context of the overall health benefits of the drug.